NEW YORK (GenomeWeb) – BioSequence has embarked on a year-long study of OncoDNA's OncoDeep CUP service in Spain, looking to raise the profile of the genomic offering among clinicians, and to strengthen its case for reimbursement.

With a population of 46 million, Spain is one of Europe's larger markets, and one where the adoption of the cancer of unknown primary test could translate into adoption in neighboring Portugal, as well as in Latin America, a region that Valencia-based BioSequence also serves.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.